A panelist discusses how the COAT trial showed that switching patients with uncontrolled dry eye disease on cyclosporine 0.05% to the 0.09% solution led to significant improvements in corneal staining ...
12d
Biogen Advances New SKYCLARYS Formulation in Early Trial, Supporting Long-Term Rare Disease Strategy
Biogen Inc. announced an update on their ongoing clinical study. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing tools for smarter, sharper dec ...
Phase III trial successfully achieved its primary endpoint and key secondary endpoints with high statistical significance Levacetylleucine demonstrated clinically meaningful improvements in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback